Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment

Table 1 Clinical outcome of hepatitis C virus-positive diffuse large B-cell lymphoma patients according to retrospective studies

Ref.	DLBCL-HCV positive patients (n)	Treatment	PFS/EFS (3 yr)	OS (3 yr)
Besson et al[16]	26	Intensive protocols	53%	56%
Visco et al[14]	156	CHOP and CHOP-like/R-CHOP	60%	80%
Park et al[15]	32	CHOP(18)/R-CHOP(11)	54.7% at 5 yr	59.2% at 5 yr
Tomita et al[17]	25	CHOP/CHOP-like	NA	46%
Ennishi et al[60]	131	R-CHOP	69%	75%
Merli et al[59]	535	CHOP(214)/+R-CHOP (252)	53%	68%
			(58% for R-CHOP)	(71% for R-CHOP)

DLBCL: Diffuse large B-cell lymphoma; CHOP: Cyclophosphamide, hydroxydaunorubicin, vincristine, prednisolone; PFS/EFS: Progression-free survival/event-free survival; OS: Overall survival; HCV: Hepatitis C virus.